GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

HPN-100

Company
Amgen
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for HPN-100 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06887777

    Efficacy and Safety of the Treatment of Pyruvate Dehydrogenase Deficiency Patients With Glycerol Phenylbutyrate (RAVICTI)

    Not yet reported Assistance Publique - Hôpitaux de Paris 15 participants Est. completion 2027-04-01 1 site
    Other conditions: Pyruvate Dehydrogenase Complex Deficiency Disease
    View official trial listing →
  • Recruiting NCT NCT06904027

    A Clinical Study of Glycerol Phenylbutyrate in Chinese Patients With Urea Cycle Disorders

    Tongji Hospital 40 participants Est. completion 2031-07 5 sites
    Other conditions: Urea Cycle Disorders
    View official trial listing →
  • Completed NCT NCT00551200

    Dose-Escalation Safety Study of HPN-100 to Treat Urea Cycle Disorders

    Not yet reported Amgen 14 participants Est. completion 2008-12 2 sites
    Other conditions: Urea Cycle Disorders
    View official trial listing →
  • Completed NCT NCT00947297

    Study of the Safety of HPN (Hyperion)-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD)

    Not yet reported Amgen 60 participants Est. completion 2011-11 22 sites Stand-alone
    Other conditions: Urea Cycle Disorders
    View official trial listing →
  • Completed NCT NCT00947544

    Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children With Urea Cycle Disorders

    Not yet reported Amgen 17 participants Est. completion 2011-08 8 sites Stand-alone
    Other conditions: Urea Cycle Disorders
    View official trial listing →
  • Completed NCT NCT00977600

    A Study of Glyceryl Tri-(4-phenylbutyrate) (GT4P)

    Not yet reported Amgen 24 participants Est. completion 2005-07 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT00986895

    A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group

    Not yet reported Amgen 32 participants Est. completion 2007-06 2 sites
    Other conditions: Hepatic Encephalopathy, Urea Cycle Disorders
    View official trial listing →
  • Completed NCT NCT00992459

    Efficacy and Safety of HPN-100 for the Treatment of Adults With Urea Cycle Disorders

    Not yet reported Amgen 46 participants Est. completion 2010-09 22 sites Stand-alone
    Other conditions: Urea Cycle Disorders
    View official trial listing →
  • Completed NCT NCT00999167

    A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy

    Not yet reported Amgen 189 participants Est. completion 2012-04 28 sites Stand-alone
    Other conditions: Cirrhosis, Hepatic Encephalopathy
    View official trial listing →
  • Completed NCT NCT01135680

    Double-Blind Randomized Crossover Trial to Access Electrocardiogram Effects of HPN-100

    Not yet reported Amgen 98 participants Est. completion 2010-09 1 site
    Other conditions: Drug Toxicity
    View official trial listing →
  • Completed NCT NCT01257737

    To Evaluate the Safety of Long-term Use of HPN-100 in the Management of Urea Cycle Disorders (UCDs)

    Not yet reported Amgen 88 participants Est. completion 2017-02-16 16 sites Stand-alone
    Other conditions: Urea Cycle Disorders
    View official trial listing →
  • Completed NCT NCT01347073

    Study of the Safety, Pharmacokinetics and Efficacy of HPN-100, in Pediatric Subjects With Urea Cycle Disorders (UCDs)

    Not yet reported Amgen 23 participants Est. completion 2013-03 8 sites Stand-alone
    Other conditions: Urea Cycle Disorders
    View official trial listing →
  • Completed NCT NCT01881984

    Use of Ravicti™ in Patients With MCAD Deficiency With the 985A>G (K304E) Mutation

    Not yet reported University of Pittsburgh 4 participants Est. completion 2016-02 1 site
    Other conditions: Medium-chain Acyl-CoA Dehydrogenase (MCAD) Deficiency
    View official trial listing →
  • Terminated NCT NCT01948427

    Observational Study That Will Collect Information on Patients With Urea Cycle Disorders (UCDs)

    Amgen 203 participants Est. completion 2020-02-24 1 site
    Other conditions: Urea Cycle Disorder
    View official trial listing →
  • No Longer Available NCT NCT01949766

    Transition From Buphenyl to RAVICTI for the Therapy of Byler Disease

    University of Pittsburgh
    Other conditions: Byler Disease
    View official trial listing →
  • Completed NCT NCT02046434

    Phenylbutyrate Response as a Biomarker for Alpha-synuclein Clearance From the Brain

    Not yet reported University of Colorado, Denver 38 participants Est. completion 2019-09 1 site
    Other conditions: Parkinson's Disease
    View official trial listing →
  • No Longer Available NCT NCT02094222

    Expanded Access Protocol for an Intermediate Size Population - RAVICTI for Byler Disease

    Robert Squires, Jr.
    Other conditions: Byler Disease
    View official trial listing →
  • Completed NCT NCT02246218

    A Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate in Pediatric Subjects Under 2 Years of Age With Urea Cycle Disorders

    Not yet reported Amgen 27 participants Est. completion 2017-07-17 17 sites
    Other conditions: Urea Cycle Disorder
    View official trial listing →
  • Terminated NCT NCT02323100

    Glycerol Phenylbutyrate Corrector Therapy For CF (Cystic Fibrosis)

    Not yet reported, Not yet reported National Jewish Health 16 participants Est. completion 2022-03-01 3 sites
    Other conditions: Cystic Fibrosis
    View official trial listing →
  • Completed NCT NCT03335488

    Study of Glycerol Phenylbutyrate & Sodium Phenylbutyrate in Phenylbutyrate Naïve Patients With Urea Cycle Disorders (UCDs)

    Not yet reported Amgen 16 participants Est. completion 2022-12-20 11 sites
    Other conditions: Urea Cycle Disorder
    View official trial listing →
  • Suspended NCT NCT04041232

    PBA Use for Treatment of ATF6-/- Patients

    Not yet reported Columbia University 2 participants Est. completion 2027-08 1 site
    Other conditions: ACHROMATOPSIA 7, Achromatopsia
    View official trial listing →
  • Active, not recruiting NCT NCT04937062

    Phenylbutyrate for Monogenetic Developmental and Epileptic Encephalopathy

    Not yet reported Weill Medical College of Cornell University 50 participants Est. completion 2026-12-31 2 sites
    Other conditions: STXBP1 Encephalopathy With Epilepsy, SLC6A1 Neurodevelopmental Disorder, Developmental and Epileptic Encephalopathy
    View official trial listing →
  • Status unknown NCT NCT05019417

    Glycerol-Phenylbutyrate Treatment in Children With MCT Mutation (Allan-Herndon- Dudley Syndrome)

    Not yet reported, Not yet reported Kaplan Medical Center 6 participants Est. completion 2022-08-30 1 site
    Other conditions: Monocarboxylate Transporter 8 Deficiency
    View official trial listing →
  • Active, not recruiting NCT NCT05983588

    PROFIL Study to Investigate the Effect of GPB on NfL Levels in Patients With Corticobasal Syndrome (CBS)

    Not yet reported Technical University of Munich 32 participants Est. completion 2026-03-30 2 sites
    Other conditions: Corticobasal Syndrome (CBS)
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.